Individual tickets or tables are now available to purchase for the awards on the 14th May, taking place at the Chelsea Harbour Hotel.
News
London aiming to stop HIV infections for good
In January it was reported that among gay, bisexual and other men who have sex with men, the prevalence of HIV transmission has fallen by a staggering 71%.
Bayer’s Eylea proves efficacy, safety in ALTAIR study
The study evaluated two different Treat and Extend (T&E) dosing regimens in patients with wet AMD.
London Cancer Hub receives major investment
The hub has secured £8.4 million in funding.
Gilead joins GSK, J&J in offering coronavirus vaccine options
The pharma giant is offering its experimental remdesivir in the running for the optimal vaccine candidate.
Palforzia becomes first peanut allergy drug to get US approval
The approval marks a “defining moment” for the peanut allergy community.
Pharmacists ‘embracing online channels’ for wider reach
Only 7% of pharmacists believe it is not important for their pharmacy to have an online presence.
Survey reveals ‘key barriers’ limiting PCSK9is prescribing
Just 6% of cardiologists are currently prescribing PCSK9is, despite 97% believing in their abilities.
NICE to request Aimovig evidence, appeal panel rules
NICE initially rejected NHS funding for the monoclonal antibody in January last year, deeming it “too costly” for the service.
RCPE launches strategy to improve health & patient care
The “ambitious” new strategy is dubbed “Towards 2025 Together”.
UK coronavirus info campaign launched
By last Tuesday, the death toll in China stood at more than 420, and the Chinese government had reported 20,438 confirmed cases.
BMS withdraws EU Opdivo/Yervoy application
The application was initially filed in 2018 for patients with first-line NSCLC.
GSK to join global effort to develop coronavirus vaccine
Last week WHO declared the outbreak an official global health emergency.
Rinvoq NICE approval could benefit 54,000 people
Rinvoq has already been available in the US since last August, and in Europe since December.
EMA accepts GSK’s belantamab mafodotin application
The drug was also accepted for accelerated assessment by the EMA’s Committee for Human Medicinal Products (CHMP).
